X37
Kiersten is a Managing Partner at DCVC Bio. Prior to DCVC, Kiersten was an Investment Director at Monsanto Growth Ventures (MGV), the Venture Capital arm of Monsanto, which was one of the most active investors globally in agriculture. Kiersten has over 15 years of experience in Biotechnology. Prior to joining MGV, Kiersten worked at Burrill & Company, which invested broadly in Life Sciences and Industrial Biotechnology. Kiersten is a co-founder and Director of Pairwise, is on the Board of Atomwise, Farmlead, Plant Response Biotech, VitalFields (acquired), Understory Weather and Blue River Technology (acquired). She is also a member of the Investment Committee of Genome Canada GAAP, The Keystone Symposia Scientific Advisory Board, and the EULC, a sport-not-for-profit. Previously, Kiersten was a Management Consultant specialized in early stage company development. She was a Scientist in Genetics & Molecular Biology at the University of Alberta and at Agriculture and Agri-Food Canada. Kiersten holds a Ph.D. in Molecular Biology & Genetics and an MBA in finance from the University of Alberta and a B.Sc. in Cellular, Molecular and Microbial Biology from the University of Calgary.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
X37
2 followers
X-37 has closed a $14.5 million Series A financing, led by DCVC Bio and joined by Alpha Intelligence Capital and Hemi Ventures. X-37 was cofounded by AtomWise and an experienced team of pharmaceutical developers from Velocity Pharmaceutical Development. With AtomWise’s top #AI platform, we have already generated promising hits against ZAP-70 for autoimmune diseases, PIM3 and SHP2 for #cancer, and Factor XIIa #anticoagulation.